Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) was the recipient of a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 503,000 shares, a growth of 96.0% from the December 31st total of 256,600 shares. Based on an average daily trading volume, of 227,800 shares, the short-interest ratio is presently 2.2 days. Approximately 6.7% of the company’s stock are sold short.
Azitra Price Performance
NYSEAMERICAN:AZTR traded down $0.06 on Wednesday, hitting $0.24. 2,499,314 shares of the company’s stock were exchanged, compared to its average volume of 4,721,041. Azitra has a 52 week low of $0.23 and a 52 week high of $40.80.
Azitra (NYSEAMERICAN:AZTR – Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.31. As a group, equities analysts predict that Azitra will post -2.78 EPS for the current year.
Azitra Company Profile
Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.
See Also
- Five stocks we like better than Azitra
- 3 Best Fintech Stocks for a Portfolio Boost
- 3 Steel Stocks Soaring After Tariff Announcements
- There Are Different Types of Stock To Invest In
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
- Profitably Trade Stocks at 52-Week Highs
- Why Salesforce Stock Could Be at Fresh Highs by February
Receive News & Ratings for Azitra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azitra and related companies with MarketBeat.com's FREE daily email newsletter.